# Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

> **NCT01049022** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 31 (actual)

## Conditions studied

- Infections

## Interventions

- **DRUG:** Moxifloxacin (Avelox, BAY12-8039)
- **DRUG:** Moxifloxacin (Avelox, BAY12-8039)
- **DRUG:** Moxifloxacin (Avelox, BAY12-8039)

## Key facts

- **NCT ID:** NCT01049022
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-12
- **Final completion:** 2013-08
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2015-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01049022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01049022, "Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01049022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*